Market Spotlight: Atopic Dermatitis
Market Spotlight: Atopic Dermatitis
$1,318.00
This Market Spotlight report covers the Atopic Dermatitis market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
Overview
Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. The condition usually begins during early infancy and childhood, but can persist into, or start during, adulthood. AD usually fluctuates between periods of relative flares and quiescence; however, some individuals have chronically active disease. The exact cause of the disease is unknown; however, certain factors such as epigenetic, genetic, immunological, and environmental interactions with overlapping skin barrier defects are indicated in its pathogenesis. The disease significantly affects the quality of life of the patient and their family, which further causes serious socioeconomic consequences. An imbalance of the Th22 and Th2 cytokines which causes the disruption of keratinocytes is thought to be an important contributing factor that drives AD pathogenesis. Furthermore, impaired skin barrier function due to mutations in the epidermal barrier protein, filaggrin, could also play a crucial role in the development of AD by increasing the penetration of microbes and allergens.
Key Takeaways
- The approved drugs in the atopic dermatitis space focus on a wide variety of targets. These drugs are commonly administered via the topical route, with a few select products being available in oral, intramuscular, intravenous, and subcutaneous formulations.
- The majority of industry-sponsored drugs in active clinical development for atopic dermatitis are in Phase II. Pipeline drugs in development for atopic dermatitis focus on a wide variety of targets. The largest proportion of drugs in development are administered via the topical route, with the remainder being oral, subcutaneous, intravenous, transdermal, and intranasal formulations.
- High-impact upcoming events for drugs in the atopic dermatitis space comprise topline Phase II, Phase IIb, Phase II/III, and Phase III trial results, as well as an expected European approval decision.
- The overall likelihood of approval of a Phase I allergy asset is 13.8%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 9.6 years from Phase I to approval in the overall allergy space.
- There have been 28 licensing and asset acquisition deals involving atopic dermatitis drugs during 2015–20. The largest deal was the $1,445m option and license agreement between Almirall and Dermira in 2019 to develop and commercialize lebrikizumab for the treatment or prevention of atopic dermatitis and certain other indications in Europe.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for atopic dermatitis have been in the early and mid-phases of development, with 66% of trials in Phase I–II, and 34% in Phase III–IV.
- The US has a substantial lead in the number of atopic dermatitis clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the atopic dermatitis space is dominated by completed trials. Novartis has the highest number of completed clinical trials for atopic dermatitis, with 71 trials.
- Novartis leads the industry sponsors with the highest number of clinical trials for atopic dermatitis, followed by Pfizer.
CONTENTS
7 OVERVIEW
8 KEY TAKEAWAYS
9 DISEASE BACKGROUND
9 Disease definition
9 Patient segmentation
9 Symptoms
9 Risk factors
10 Diagnosis
11 TREATMENT
11 Non-pharmacologic interventions
11 Medications
12 Systemic treatment
12 Biologic therapy
12 Phototherapy treatment
12 Adjunctive treatment
14 EPIDEMIOLOGY
15 MARKETED DRUGS
19 PIPELINE DRUGS
30 RECENT EVENTS AND ANALYST OPINION
30 OPA-15406 for Atopic Dermatitis (March 26, 2020)
31 BTX-1204 for Atopic Dermatitis (March 25, 2020)
33 ASN002 for Atopic Dermatitis (March 10, 2020)
35 Tradipitant for Atopic Dermatitis (February 25, 2020)
36 Ruxolitinib Cream for Atopic Dermatitis (February 19, 2020)
38 Olumiant for Atopic Dermatitis (January 30, 2020)
39 Ruxolitinib Cream for Atopic Dermatitis (January 28, 2020)
41 Olumiant for Atopic Dermatitis (January 24, 2020)
42 ARQ-151 for Atopic Dermatitis (December 16, 2019)
44 Tralokinumab for Atopic Dermatitis (December 11, 2019)
45 Etokimab for Atopic Dermatitis (November 8, 2019)
46 Abrocitinib for Atopic Dermatitis (September 27, 2019)
48 Olumiant for Atopic Dermatitis (August 23, 2019)
50 ATI-502 for Atopic Dermatitis (August 8, 2019)
51 Mapracorat for Atopic Dermatitis (June 25, 2019)
52 Abrocitinib for Atopic Dermatitis (May 15, 2019)
54 Nemolizumab for Atopic Dermatitis (April 18, 2019)
56 KEY UPCOMING EVENTS
57 KEY REGULATORY EVENTS
57 JT Gains World-First Topical JAK Inhibitor Approval
57 Getting A Good Start: Sanofi Extends Dupixent’s Potential To Younger Patients
57 CHMP Delivers More Good News For Sanofi’s Dupixent
58 PROBABILITY OF SUCCESS
59 LICENSING AND ASSET ACQUISITION DEALS
59 Reverse Merger With Tocagen Takes Forte’s Dermatology Ambitions Public
59 Deals Shaping The Medical Industry, February 2020
60 Bayer Harnessing Skin Microbiome In New Product Development
60 Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab
60 Janssen Licenses Global Rights To XBiotech’s Bermekimab
61 Seneca Moves Towards Antibody In-Licensing Deal With China’s QYuns
61 Leo Options Two Protein-Degradation Candidates Under Existing Alliance With Ubiquigent
61 Almirall Pays $50m To Stick With Dermira’s Lebrikizumab
62 PARENT PATENTS
63 REVENUE OPPORTUNITY
64 CLINICAL TRIAL LANDSCAPE
65 Sponsors by status
66 Sponsors by phase
67 Recent events
71 BIBLIOGRAPHY
72 Prescription information
73 APPENDIX
LIST OF FIGURES
19 Figure 1: Overview of pipeline drugs for atopic dermatitis in the US
19 Figure 2: Pipeline drugs for atopic dermatitis, by company
20 Figure 3: Pipeline drugs for atopic dermatitis, by drug type
20 Figure 4: Pipeline drugs for atopic dermatitis, by classification
31 Figure 5: OPA-15406 for Atopic Dermatitis (March 26, 2020): Phase III – Adults (Japan), Phase III – Pediatric (Japan)
33 Figure 6: BTX-1204 for Atopic Dermatitis (March 25, 2020): Phase II – 1204 Study
35 Figure 7: ASN002 for Atopic Dermatitis (March 10, 2020): Phase IIb – RADIANT
36 Figure 8: Tradipitant for Atopic Dermatitis (February 25, 2020): Phase III – EPIONE 1
38 Figure 9: Ruxolitinib Cream for Atopic Dermatitis (February 19, 2020): Phase III – TRuE-AD1
39 Figure 10: Olumiant for Atopic Dermatitis (January 30, 2020): Phase III – BREEZE-AD5 (Mono)
41 Figure 11: Ruxolitinib Cream for Atopic Dermatitis (January 28, 2020): Phase III – TRuE-AD2
42 Figure 12: Olumiant for Atopic Dermatitis (January 24, 2020): Phase III – BREEZE-AD4 (TCS Add-On; Ex-US)
44 Figure 13: ARQ-151 for Atopic Dermatitis (December 16, 2019): Phase IIa – Study 212
46 Figure 14: Etokimab for Atopic Dermatitis (November 8, 2019): Phase IIb – ATLAS
48 Figure 15: Abrocitinib for Atopic Dermatitis (September 27, 2019): Phase III – JADE Mono-2
50 Figure 16: Olumiant for Atopic Dermatitis (August 23, 2019): Phase III – BREEZE-AD7 (TCS Add-On; Ex-US)
51 Figure 17: ATI-502 for Atopic Dermatitis (August 8, 2019): Phase II – AD-201
54 Figure 18: Abrocitinib for Atopic Dermatitis (May 15, 2019): Phase III – JADE Mono-1
55 Figure 19: Nemolizumab for Atopic Dermatitis (April 18, 2019): Phase III – Moderate to Severe Pruritus (Japan)
56 Figure 20: Key upcoming events in atopic dermatitis
58 Figure 21: Probability of success in the atopic dermatitis pipeline
59 Figure 22: Licensing and asset acquisition deals in atopic dermatitis, 2015–20
62 Figure 23: Parent patents in atopic dermatitis
64 Figure 24: Clinical trials in atopic dermatitis
64 Figure 25: Top 10 drugs for clinical trials in atopic dermatitis
65 Figure 26: Top 10 companies for clinical trials in atopic dermatitis
65 Figure 27: Trial locations in atopic dermatitis
66 Figure 28: Atopic dermatitis trials sponsors by status
67 Figure 29: Atopic dermatitis trials sponsors by phase
LIST OF TABLES
16 Table 1: Marketed drugs for atopic dermatitis
21 Table 2: Pipeline drugs for atopic dermatitis in the US
30 Table 3: OPA-15406 for Atopic Dermatitis (March 26, 2020)
32 Table 4: BTX-1204 for Atopic Dermatitis (March 25, 2020)
34 Table 5: ASN002 for Atopic Dermatitis (March 10, 2020)
35 Table 6: Tradipitant for Atopic Dermatitis (February 25, 2020)
37 Table 7: Ruxolitinib Cream for Atopic Dermatitis (February 19, 2020)
38 Table 8: Olumiant for Atopic Dermatitis (January 30, 2020)
40 Table 9: Ruxolitinib Cream for Atopic Dermatitis (January 28, 2020)
41 Table 10: Olumiant for Atopic Dermatitis (January 24, 2020)
43 Table 11: ARQ-151 for Atopic Dermatitis (December 16, 2019)
44 Table 12: Tralokinumab for Atopic Dermatitis (December 11, 2019)
45 Table 13: Etokimab for Atopic Dermatitis (November 8, 2019)
47 Table 14: Abrocitinib for Atopic Dermatitis (September 27, 2019)
48 Table 15: Olumiant for Atopic Dermatitis (August 23, 2019)
50 Table 16: ATI-502 for Atopic Dermatitis (August 8, 2019)
52 Table 17: Mapracorat for Atopic Dermatitis (June 25, 2019)
53 Table 18: Abrocitinib for Atopic Dermatitis (May 15, 2019)
54 Table 19: Nemolizumab for Atopic Dermatitis (April 18, 2019)
63 Table 20: Historical global sales, by drug ($m), 2014–18
63 Table 21: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the